Neoadjuvant, biweekly, dose-dense chemotherapy with epirubicin and cyclophosphamide followed by docetaxel in primary breast cancer.

被引：0
|
作者：
Cramer, EM [1 ]
Moers, C [1 ]
Zarghooni, V [1 ]
Mallmann, P [1 ]
Warm, M [1 ]
机构：
[1] Univ Hosp Cologne, Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：82S / 82S
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant chemotherapy with a dose-dense sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer. Correlation between pathologic complete response (pCR) and biologic markers
    Sanchez, A.
    Duenas-Garcia, R.
    Jaen-Morago, A.
    Chacon, I.
    Garcia-Tapiador, A.
    Martinez-Ortega, E.
    de la Torre-Cabrera, C.
    Duenas, B.
    Ribelles, N.
    Sanchez-Rovira, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer
    T. Zhu
    C. L. Liu
    Y. F. Zhang
    Y. H. Liu
    F. P. Xu
    J. Zu
    G. C. Zhang
    X. R. Li
    N. Liao
    K. Wang
    Breast Cancer Research and Treatment, 2016, 156 : 117 - 124
  • [43] Sequential dose-dense 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel in patients with early breast cancer with four or more positive lymph nodes
    Murialdo, Roberto
    Gallo, Maurizio
    Boy, Davide
    Zoppoli, Gabriele
    Tixi, Lucia
    Gonella, Roberta
    Ballestrero, Alberto
    Patrone, Franco
    TUMORI JOURNAL, 2014, 100 (02): : 128 - 135
  • [44] Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients
    Sanna, G.
    Pestrin, M.
    Zafarana, E.
    Biagioni, C.
    Cavaciocchi, D.
    Turner, N.
    Di Leo, A.
    Biganzoli, L.
    BREAST, 2013, 22 (05): : 926 - 932
  • [45] Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study
    Lambert-Falls, Rosemary
    Modugno, Susan
    CLINICAL BREAST CANCER, 2007, 7 (09) : 697 - 704
  • [46] Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: A phase II study
    Kummel, S
    Thomas, A
    Paepke, S
    Schwarz, M
    Heinrich, G
    Wetzel, A
    Elling, D
    Kohls, A
    Lichtenegger, W
    Blohmer, JU
    ACTA ONCOLOGICA, 2005, 44 (03) : 248 - 254
  • [47] Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study
    Clavarezza, Matteo
    Bordonaro, Roberto
    Daniele, Bruno
    Ferrandina, Gabriella
    Barni, Sandro
    Turazza, monica
    Coati, Francesca
    De Matteis, Andrea
    De Placido, Sabino
    Cognetti, Francesco
    Olmeo, Nina Antonina
    Carrozza, Francesco
    Bruzzi, Paolo
    Del Mastro, Lucia
    ONCOLOGIST, 2013, 18 (08): : 924 - 925
  • [48] Primary chemotherapy with sequential docetaxel followed by docetaxel and epirubicin in large operable breast cancer
    Frutuoso, C.
    Henriques, I.
    Pazos, I.
    Abraul, E.
    Pego, A.
    Belo, J.
    Campos, O.
    Gervasio, H.
    De Oliveira, C.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2007, 28 (06) : 447 - 450
  • [49] Lymphopenia in dose-dense chemotherapy for early stage breast cancer.
    Tolaney, S. M.
    Partridge, A. H.
    Scheib, R. G.
    Ligibel, J. A.
    Shulman, L. N.
    Winer, E. P.
    Burstein, H. J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S112 - S112
  • [50] The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
    Wu, Xian
    Ye, Chaoran
    Wang, Xingmeng
    Cai, Ruyu
    Yang, Junzhe
    Yu, Xiafei
    Zhou, Yi
    Shen, Li
    Zhu, Yanhui
    Liu, Xiaoan
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 1517 - 1527
12345